Transformational Research 2015

The goal of the Program is to provide funding to high potential, translational research that will have transformational impact in neurodegenerative diseases of aging.  These are to be larger, longer grants (up to $1.5m for up to 3 years) for transformational work including international collaborations.

Transformational Research 2015 Awardees

A new approach to address motor and non-motor complications of Parkinson’s disease

Grantees: Dr. Philippe Huot , Dr. Claude Rouillard , Dr. Michel Panisset , Dr. Jean DaSilva

Project description Psychosis and abnormal involuntary movements (dyskinesia) affect over 50% of patients with Parkinson’s disease, however, there are few available therapies. In this project, we will seek new...


Tissue-engineered skin model of ALS to accelerate biomarkers and drug discoveries

Grantees: Dr. Francois Gros-Louis

Project description Many specific skin changes have been repeatedly reported in ALS patients, but never as yet fully explained. Such skin manifestations have never been studied systematically due to...


Chemical suppressors of nonsense mutations for the treatment of frontotemporal dementia

Grantees: Dr. Haakon Nygaard , Dr. Michel Roberge , Dr. Howard Feldman , Dr. Ian Mackenzie

Project description The principal role of the human genome is to produce proteins that serve as building blocks for all aspects of the body, including the brain. During protein...


Development of a treatment of Alzheimer based on the editing of the Amyloid Precuror Protein gene with the CRISPR system

Grantees: Dr. Jacques Tremblay

Project description Alzheimer’s disease (AD) is characterized by progressive memory lost due to abnormal function and death of neurons. This is due to the accumulation in the patient’s brain...


Development of a novel progressive rat model of Parkinson’s disease

Grantees: Dr. Jackalina Van Kampen , Dr. Harold Robertson , Dr. Doris Doudet , Dr. Michael Schlossmacher , Dr. R. Andrew Tasker , Dr. Denis Soulet

Project description The development of effective neuroprotective therapies for Parkinson’s disease (PD) has been severely hindered by the notable lack of an appropriate animal model for preclinical screening. Indeed,...